Abstract: In the context of the big data era, the extensive penetration of the Internet and the rapid development of database technology have led to an explosive growth in the amount of data generated ...

Snack-Sized Version: Legend Biotech will present new data for its cancer therapy, CARVYKTI, at a medical conference in February 2026. The presentations will highlight long-term efficacy and real-world ...

Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan.

Legend Biotech Corp’s stock is navigating a period of significant market turbulence. A downward trend has persisted for the equity, even as the company continues to report impressive clinical ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- ...

Greetings, and welcome to enGene's conference call to discuss the company's preliminary LEGEND data. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to ...

--Down 51.49% from its all-time closing high of $76.50 on July 28, 2023 --Down 34.79% from 52 weeks ago (Aug. 8, 2024), when it closed at $56.91 --Down 35.52% from ...